TSC-100
Cell therapy
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ALLOHA NCT05473910 · AML Registry: NCT05473910 | 1 | Occurrence of dose limiting toxicities (2 years); Occurrence of adverse events (2 years) 2026-06-01 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Hematologic Malignancies: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| TSC-100: this drug | Phase 1 | Cell therapy | HA-1 minor histocompatibility antigen (HLA-A*02:01) | not yet graded | No reviewed efficacy summary in this indication | |
| TSC-101 | Phase 3 | Cell therapy | HA-2 (minor histocompatibility antigen) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.